RxBiologics is part of the RxCelerate group of companies. RxCelerate, was founded in 2013, with a vision to provide a bespoke high quality outsourced drug discovery and development platform. In 2018, RxCelerate made the decision to collaborate with Jonny Finlay, an experienced biotech antibody engineer, and invest in building from first principles a world-leading biologics antibody discovery platform to generate lead antibodies with the desired drug like properties from the beginning.
World-leading biologics antibody discovery
The RxBiologics Galaxy™ Antibody Discovery Platform together with RxCelerate biology, in-silico design, chemistry and programme management capabilities, enables us to deliver this vision for biologics drug discovery programmes. We provide comprehensive work packages to support client projects from early discovery through preclinical phases.